Cytek Biosciences, Inc. CTKB
5.65
(0.08)
(1.40%)
as of 25 Sep
- Market cap
- $744.8M
- P/E
- 0.0×
Follow CTKB
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (23.04%) | (20.93%) | (18.05%) | (3.36%) |
+8 more TTM periods Free account |
|
| (17.14%) | (15.89%) | (13.85%) | (2.60%) | ||
ROIC |
(46.36%) | (41.67%) | (31.26%) | (16.92%) | |
Return on Tangible Assets |
(25.63%) | (23.21%) | (20.03%) | (3.87%) | |
Average Days of Receivables |
87.76 | 92.79 | 113.23 | 105.02 | |
Free Cash Flow per Share |
(0.09) | (0.10) | (0.07) | (0.04) | |
Free Cash Flow |
(11.97) | (12.61) | (8.62) | (5.73) | |
Capital Expenditures |
(5.93) | (5.31) | (3.94) | (3.81) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(1.03%) | (1.24%) | (0.78%) | (0.30%) | |
Accounts Receivable Turnover |
3.90 | 3.82 | 3.27 | 3.60 | |
Accounts Payable Turnover |
12.67 | 15.19 | 16.25 | 14.07 | |
Inventory Turnover |
1.90 | 2.07 | 2.10 | 1.86 | |
Average Days of Payables |
31.74 | 24.95 | 24.11 | 30.41 | |
Days of Inventory on Hand |
197.27 | 184.29 | 182.17 | 205.80 | |
Tax Rate |
0.97 | 1.06 | 1.23 | (0.17) | |
Research and Development Expense of Revenue |
18.03% | 17.80% | 18.10% | 18.91% | |
Selling, General and Administrative Expense of Revenue |
56.80% | 55.39% | 53.79% | 50.71% | |
Share Based Compensation of Revenue |
10.34% | 11.17% | 12.20% | 13.24% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.07 | 0.10 | 0.07 | 0.15 | |
Depreciation/Fixed assets |
0.57 | 0.58 | 0.66 | 0.65 | |
Capex/Depreciation |
(0.50) | (0.45) | (0.33) | (0.33) | |
Revenue per Share |
1.60 | 1.59 | 1.58 | 1.54 | |
Operating CF per Share |
(0.05) | (0.06) | (0.04) | (0.01) | |
Capex per Share |
(0.05) | (0.04) | (0.03) | (0.03) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Net Profit Margin |
(38.98%) | (36.25%) | (33.02%) | (6.51%) |
Columns are period end dates